Business Context and Reporting Period
Kyntra Bio, Inc. (formerly FibroGen, Inc.) is a biopharmaceutical company focused on oncology and anemia therapies. The company rebranded to Kyntra Bio in January 2026, with its stock trading under the symbol "KYNB" on the Nasdaq Global Select Market. This Form 10-K covers the fiscal year ended December 31, 2025. The company's primary assets include roxadustat (approved for anemia in chronic kidney disease in Europe, Japan, and China) and FG-3246, an antibody-drug conjugate in Phase 2 development for metastatic castration-resistant prostate cancer (mCRPC).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue (Continuing Operations) | $6.4 million | $29.6 million |
| Loss from Continuing Operations | $(58.2) million | $(153.1) million |
| Net Income (Including Discontinued Ops) | $183.5 million | $(47.6) million |
| Cash and Cash Equivalents | $47.9 million | $50.5 million |
| Short-term and Long-term Investments | $61.3 million | $0 |
| Total Liquidity (Cash + Investments + AR) | $109.4 million | $50.5 million |
| Accumulated Deficit | $(1.7) billion | $(1.9) billion |
Note: 2025 Net Income includes a $241.7 million gain from discontinued operations related to the sale of China assets.
Material Changes vs. Prior Period
- Divestiture of China Operations: On August 29, 2025, the company sold its China operations (FibroGen International) to AstraZeneca for a total consideration of $220.4 million ($85.0 million enterprise value + $135.4 million net cash). This transaction was classified as discontinued operations, resulting in a $52.6 million gain on divestiture.
- Revenue Decline: Continuing operations revenue dropped 78% to $6.4 million, primarily due to the termination of the AstraZeneca U.S./Rest of World agreement in early 2024, which eliminated a significant revenue stream recognized in the prior year.
- Expense Reduction: Total operating costs and expenses decreased by $127.7 million (71%) to $52.3 million. This was driven by a $18.9 million reduction in restructuring charges (non-recurring in 2025), lower clinical trial costs following the termination of the pamrevlumab program, and workforce reductions.
- Debt Repayment: The company repaid its $75.0 million senior secured term loan facility with Morgan Stanley Tactical Value in August 2025 using proceeds from the China divestiture, incurring a $6.6 million loss on debt extinguishment.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- Roxadustat (MDS): The company submitted a Phase 3 trial protocol to the FDA in December 2025 for roxadustat in anemia associated with lower-risk myelodysplastic syndromes (MDS). The FDA granted Orphan Drug Designation for this indication in December 2025.
- FG-3246 (mCRPC): A Phase 2 monotherapy dose optimization study is ongoing, with interim results expected in the second half of 2026. The program includes the development of FG-3180, a companion PET imaging agent.
Risks and Contingencies:
- Manufacturing Supply Chain: The company relies on single-source suppliers in China (WuXi STA for API) and faces risks related to U.S. legislation impacting WuXi AppTec and its affiliates, which could disrupt the supply of FG-3246 and roxadustat.
- Liquidity: While the divestiture alleviated immediate going-concern doubts, the company anticipates continued losses and may require additional financing to fund operations and clinical trials.
- Revenue Interest Financing: The company has a liability related to the sale of future revenues (RIFA) with NovaQuest, with a payment cap of up to $125.0 million by 2031.
- Legal Proceedings: The company settled a class action lawsuit for $28.5 million (fully covered by insurance) and paid a $1.25 million civil penalty to the SEC in 2025.
Investor Verification Checklist
- Divestiture Holdbacks: Verify the status of the remaining $4.0 million holdback from the AstraZeneca sale, which is subject to indemnity claims and may not be fully received.
- Manufacturing Dependencies: Confirm the company's contingency plans for API supply given the geopolitical risks and U.S. legislative scrutiny surrounding WuXi AppTec and its subsidiaries.
- Phase 3 MDS Trial: Monitor the initiation and enrollment progress of the roxadustat Phase 3 trial for MDS, as this is a critical value driver for the U.S. market.
- FG-3246 Interim Data: Await the interim results of the Phase 2 mCRPC study expected in late 2026 to assess the drug's efficacy and optimal dosing.
- Capital Requirements: Assess the runway provided by the current $109.4 million in liquidity against the projected burn rate for the MDS and FG-3246 programs.